Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Biological: GNR-069
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 160
- Registration Number
- NCT05492409
- Locations
- 🇷🇺
State Budgetary Institution of Healthcare Irkutsk awarded the "Sign of Honor" Order Regional Clinical Hospital, Irkutsk, Irkutsk Region, Russian Federation
🇷🇺State Budgetary Health Institution of the Kaluga Region "Kaluga Regional Clinical Hospital", Kaluga, Kaluga Region, Russian Federation
🇷🇺State budgetary institution of health care of the Nizhny Novgorod region "Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko", Nizhny Novgorod, Nizhny Novgorod Region, Russian Federation
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Biological: NplateBiological: GNR-069
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 160
- Registration Number
- NCT05220878
- Locations
- 🇷🇺
State Budgetary Institution of Healthcare Irkutsk awarded the "Sign of Honor" Order Regional Clinical Hospital, Irkutsk, Irkutsk Region, Russian Federation
🇷🇺State Budgetary Health Institution of the Kaluga Region "Kaluga Regional Clinical Hospital", Kaluga, Kaluga Region, Russian Federation
🇷🇺State Autonomous Healthcare Institution "Kuzbass Clinical Hospital named after S.V. Belyaev", Kemerovo, Kemerovo Region, Russian Federation
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- Conditions
- Mucopolysaccharidosis Type IIMetabolic Diseases
- Interventions
- Drug: GNR-055 1.0-2.0-3.0 mg/kgDrug: GNR-055 2.0 mg/kgDrug: GNR-055 3.0 mg/kg
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 32
- Registration Number
- NCT05208281
- Locations
- 🇷🇺
State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital, Ekaterinburg, Russian Federation
🇷🇺Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences), Moscow, Russian Federation
🇷🇺V.I. Vernadsky Crimean Federal University, Simferopol, Russian Federation
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: GNR-038, 50 МЕ/ kgDrug: GNR-038. The dose will be selected according to results of stage 1 clinical trial.Drug: PlaceboDrug: Berinert®, 20 МЕ/ kgDrug: GNR-038, 100 МЕ/ kg
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- AO GENERIUM
- Registration Number
- NCT04898309
- Locations
- 🇷🇺
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow, Russian Federation
🇷🇺Moscow City Clinical Hospital 52, Moscow, Russian Federation
🇷🇺Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Moscow, Russian Federation
Observational Study of Elizaria® in aHUS Patients
- Conditions
- aHUSAtypical Hemolytic Uremic Syndrome
- Interventions
- Drug: Elizaria®
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 50
- Registration Number
- NCT04749810
- Locations
- 🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" of the Ministry of Health of the Russian Federation, Kazan, Russian Federation
🇷🇺Regional State Budgetary Healthcare Institution "Krasnoyarsk' Regional Clinical Center for Maternity and Childhood Protection", Krasnoyarsk, Russian Federation
🇷🇺State budgetary healthcare institution of the city of Moscow "Children's City Clinical Hospital of St. Vladimir of the Healthcare Department of the City of Moscow", Moscow, Russian Federation
A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Biological: Eculizumab (JSC GENERIUM, Russia)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 50
- Registration Number
- NCT04679103
- Locations
- 🇷🇺
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Chelyabinsk Region, Russian Federation
🇷🇺Federal State Budgetary Institution of Science "Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency", Kirov, Kirov Region, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov", Saint Petersburg, Leningrad Region, Russian Federation
Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 44
- Registration Number
- NCT04671810
- Locations
- 🇷🇺
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Chelyabinsk Region, Russian Federation
🇷🇺State Budgetary Institution of Healthcare Irkutsk Order of the "Badge of Honor" Regional Clinical Hospital, Irkutsk, Irkutsk Region, Russian Federation
🇷🇺State Budgetary Institution of Healthcare of the City of Moscow City Clinical Hospital named after S.P. Botkin of the Moscow Department of Health, Moscow, Moscow Region, Russian Federation
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
- Conditions
- Age Related Macular Degeneration (ARMD)
- Interventions
- Biological: GNR-067Biological: Lucentis®
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 408
- Registration Number
- NCT04667039
- Locations
- 🇷🇺
Regional budgetary healthcare institution "Ivanovo Regional Clinical Hospital", Ivanovo, Ivanovo Region, Russian Federation
🇷🇺State Budgetary Healthcare Facility of the St. Petersburg Region "First St. Petersburg State Medical University named after academician I.P. Pavlova "of the Ministry of Health of the Russian Federation, Saint Petersburg, Leningrad Region, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education "Moscow State University of Medicine and Dentistry named after A.I. Evdokimov "of the Ministry of Health of the Russian Federation, Moscow, Moscow Region, Russian Federation
An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma
- Conditions
- Bronchial Asthma
- Interventions
- Biological: Genolar® + Symbicort®Biological: Xolair® + Symbicort®
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 192
- Registration Number
- NCT04607629
- Locations
- 🇷🇺
Limited Liability Company "MDP-Medical Group", Odintsovo, Moscow Region, Russian Federation
🇷🇺State Budgetary Healthcare Institution of the Perm Territory "Clinical Medical and Sanitary Unit No. 1, Perm, Perm Territory, Russian Federation
🇷🇺State Budgetary Healthcare Institution "Republican Clinical Hospital named after G.G. Kuvatov", Ufa, Republic Of Bashkortostan, Russian Federation
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
- Conditions
- ALLGNR-084B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Biological: Cohort 1, GNR-084Biological: Cohort 2, GNR-084Biological: Cohort 5, GNR-084Biological: Cohort 6, GNR-084Biological: Cohort 3, GNR-084Biological: Cohort 4, GNR-084
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- AO GENERIUM
- Target Recruit Count
- 36
- Registration Number
- NCT04601584
- Locations
- 🇷🇺
Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia), Moscow, Russian Federation
🇷🇺Almazov National Medical Research Centre, Saint Petersburg, Russian Federation
🇷🇺Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation